(Q38071693)

28 August 2017

1 reference

title

Update on biologicals for treatment of juvenile idiopathic arthritis (English)

1 reference

juvenile rheumatoid arthritis

28 August 2017

main subject

1 reference

Gerd Horneff

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

5 January 2013

1 reference

Expert Opinion on Biological Therapy

28 August 2017

published in

1 reference

28 August 2017

volume

13

1 reference

28 August 2017

issue

3

1 reference

28 August 2017

page(s)

361-376

1 reference

Cytokines in autoimmunity

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Treatment strategies for juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

The German etanercept registry for treatment of juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Factors associated with treatment response to etanercept in juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Onset of multiple sclerosis associated with anti-TNF therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Rates of malignancy associated with juvenile idiopathic arthritis and its treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Adalimumab in the therapy of uveitis in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Anakinra for systemic juvenile arthritis: the Rocky Mountain experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Prevention and reversal of nephritis in MRL/lpr mice with a single injection of C-reactive protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Use of canakinumab in the cryopyrin-associated periodic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Successful treatment of resistant pseudogout with anakinra

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

B cell depletion for autoimmune diseases in paediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.735657

10.1517/14712598.2013.735657

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference